The library will be closed between August 10, 2026 and August 16, 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Hevessy, Z.,
Tóth, G.,
Antal-Szalmás, P.,
Tőkés-Füzesi, M.,
Kappelmayer, J.,
Kárai, B.,
Ajzner, É.,
Working Group on Guidelines,
Algorithms of the Hungarian Society of Laboratory Medicine:
Algorithm of differential diagnosis of anemia involving laboratory medicine specialists to advance diagnostic excellence.
Clin. Chem. Lab. Med. 62 (3), 410-420, 2024.
Tóth, G.,
Szöllősi, J.,
Abken, H.,
Vereb, G.,
Szöőr, Á.:
A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.
Int. J. Mol. Sci. 21 (3), 1-11, (article identifier: 1039), 2020.
Szöőr, Á.,
Tóth, G.,
Zsebik, B.,
Szabó, V.,
Eshhar, Z.,
Abken, H.,
Vereb, G.:
Trastuzumab Derived HER2-specific CARs for the Treatment of Trastuzumab-Resistant Breast Cancer: CAR T Cells Penetrate and Eradicate Tumors That Are Not Accessible to Antibodies.
Cancer Lett. 484, 1-8, 2020.
Tóth, G.,
Szöllősi, J.,
Vereb, G.:
Quantitating ADCC against adherent cells: impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
Cytom. Part A. 91 (10), 1021-1029, 2017.
Tóth, G.,
Szöőr, Á.,
Simon, L.,
Yarden, Y.,
Szöllősi, J.,
Vereb, G.:
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
mAbs. 8 (7), 1361-1370, 2016.
